MY176246A - Compositions for oral administration of zoledronic acid or related compounds for treating disease - Google Patents

Compositions for oral administration of zoledronic acid or related compounds for treating disease

Info

Publication number
MY176246A
MY176246A MYPI2016701480A MYPI2016701480A MY176246A MY 176246 A MY176246 A MY 176246A MY PI2016701480 A MYPI2016701480 A MY PI2016701480A MY PI2016701480 A MYPI2016701480 A MY PI2016701480A MY 176246 A MY176246 A MY 176246A
Authority
MY
Malaysia
Prior art keywords
zoledronic acid
compositions
oral administration
related compounds
treating disease
Prior art date
Application number
MYPI2016701480A
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/063,979 external-priority patent/US8802658B2/en
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of MY176246A publication Critical patent/MY176246A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
MYPI2016701480A 2013-10-25 2014-08-08 Compositions for oral administration of zoledronic acid or related compounds for treating disease MY176246A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/063,979 US8802658B2 (en) 2012-05-14 2013-10-25 Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/279,241 US20140249317A1 (en) 2012-05-14 2014-05-15 Compositions for oral administration of zoledronic acid or related compounds for treating disease

Publications (1)

Publication Number Publication Date
MY176246A true MY176246A (en) 2020-07-24

Family

ID=52993341

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016701480A MY176246A (en) 2013-10-25 2014-08-08 Compositions for oral administration of zoledronic acid or related compounds for treating disease

Country Status (12)

Country Link
EP (1) EP3060220A4 (en)
JP (6) JP6166471B2 (en)
KR (3) KR101975687B1 (en)
CN (2) CN108434154A (en)
AU (2) AU2014340649C1 (en)
CA (1) CA2928350C (en)
HK (1) HK1257400A1 (en)
IL (2) IL245287A0 (en)
MX (1) MX2016005396A (en)
MY (1) MY176246A (en)
SG (3) SG10201800001VA (en)
WO (1) WO2015060924A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
JP6166471B2 (en) * 2013-10-25 2017-07-19 アンテシップ バイオベンチャーズ トゥー エルエルシー Method for preparing an oral dosage form with enhanced oral bioavailability of zoledronic acid
CN109891021B (en) 2016-10-28 2022-04-12 三菱化学株式会社 Sizing agent for carbon fiber, aqueous dispersion of sizing agent for carbon fiber, and carbon fiber bundle having sizing agent attached thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
JP2004528340A (en) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト Pharmaceutical use of bisphosphonates
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
US20050054616A1 (en) * 2003-07-03 2005-03-10 Judith Aronhime Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
AR046773A1 (en) * 2003-12-23 2005-12-21 Novartis Ag PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES
ES2650665T3 (en) * 2009-07-31 2018-01-19 Grünenthal GmbH Crystallization and bioavailability method
JP5792748B2 (en) * 2010-02-06 2015-10-14 タール ファーマシューティカルズ，インコーポレイテッド Crystallization and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
SI2849758T1 (en) * 2012-05-14 2018-07-31 Anatecip Bioventures Ii Llc Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
JP6166471B2 (en) * 2013-10-25 2017-07-19 アンテシップ バイオベンチャーズ トゥー エルエルシー Method for preparing an oral dosage form with enhanced oral bioavailability of zoledronic acid

Also Published As

Publication number Publication date
SG11201603042TA (en) 2016-05-30
JP2017200941A (en) 2017-11-09
SG10201800001VA (en) 2018-02-27
CN108434154A (en) 2018-08-24
IL245287A0 (en) 2016-06-30
EP3060220A1 (en) 2016-08-31
JP2016534081A (en) 2016-11-04
CN105960240A (en) 2016-09-21
SG10201609548UA (en) 2016-12-29
CN105960240B (en) 2018-04-20
AU2014340649C1 (en) 2017-05-18
MX2016005396A (en) 2017-03-01
JP6802245B2 (en) 2020-12-16
IL254123A0 (en) 2017-10-31
JP2022162105A (en) 2022-10-21
JP6166471B2 (en) 2017-07-19
AU2017200832A1 (en) 2017-03-02
KR101739244B1 (en) 2017-05-23
KR20160062177A (en) 2016-06-01
AU2014340649B2 (en) 2016-11-17
JP2024040304A (en) 2024-03-25
WO2015060924A1 (en) 2015-04-30
CA2928350C (en) 2018-01-09
HK1257400A1 (en) 2019-10-18
EP3060220A4 (en) 2017-05-31
JP2019059771A (en) 2019-04-18
KR20170058444A (en) 2017-05-26
CA2928350A1 (en) 2015-04-30
KR101975687B1 (en) 2019-05-07
KR20190009428A (en) 2019-01-28
JP2021028343A (en) 2021-02-25
JP7136487B2 (en) 2022-09-13
JP6453387B2 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
NZ702414A (en) Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
MX2020010300A (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof.
EA201890767A1 (en) C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER APPLICATIONS
PH12016502352A1 (en) Pharmaceutical composition
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2016000294A (en) Pharmaceutical composition for a sustained release of lanreotide.
MX2017009849A (en) Monomethylfumarate prodrug compositions.
PH12014502065A1 (en) Vesicular formulations
EA201591704A1 (en) NEW SUSTAINABLE SALTS OF PENTADECEPEPTIDE, METHOD OF THEIR PRODUCTION, THEIR APPLICATION IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THERAPY
BR112017002449A2 (en) treatment of symptoms associated with androgen deprivation therapy
MX2014014817A (en) Compounds for treating inflammation and pain.
MX2014011520A (en) Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections.
PH12015502703A1 (en) Pharmaceutical compositions
MX2016002139A (en) Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate.
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
MY196155A (en) Osteoclast Inhibitors for Pain